Evidence mapPaperPMID 33960724Full record

ArticleESC heart failure2021

Heart failure related to adult congenital heart disease: prevalence, outcome and risk factors.

Stijn Arnaert, Pieter De Meester, Els Troost, Walter Droogne, Lucas Van Aelst, Johan Van Cleemput, Gabor Voros, Marc Gewillig, Bjorn Cools, Philip Moons and 5 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05580510 ("An Open-label Clinical Trial to Evaluate the Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan in Adult Patients With Chronic Heart Failure With Reduced Ejection Fraction Associated With Congenital Heart Disease"), which is not on this map. Cited by 35 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 3 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05580510 phase2 / phase3unknown statusstarted 2023, after this paper: background citation

"An Open-label Clinical Trial to Evaluate the Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan in Adult Patients With Chronic Heart Failure With Reduced Ejection Fraction Associated With Congenital Heart Disease"

Ran2023Enrolled160Registered outcomes9Posted comparisons0ConditionsCongenital Heart Disease, Heart Failure, Heart Failure With Reduced Ejection FractionArmsEmpagliflozin 10 MG OD, Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID
Open the trial in the graph
3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. A Systematic Review and Meta-Analysis of the Safety and Efficacy of SGLT2 Inhibitors in Chronic Heart Failure in ACHD Patients.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025
    Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Medical Therapy for Heart Failure in Adult Congenital Heart Disease Patients.Structural heart : the journal of the Heart Team · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 3 countries.

Stijn ArnaertFaculty of Medicine, Department of Internal Medicine, KU Leuven, Leuven, Belgium.
Pieter De MeesterDivision of Structural and Congenital Cardiology, University Hospitals Leuven, Leuven, Belgium.
Els TroostDivision of Structural and Congenital Cardiology, University Hospitals Leuven, Leuven, Belgium.
Walter DroogneDepartment of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
Lucas Van AelstDepartment of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
Johan Van CleemputDepartment of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
Gabor VorosDepartment of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
Marc GewilligDepartment of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
Bjorn CoolsDepartment of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
Philip MoonsDepartment of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
Filip RegaDepartment of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
Bart MeynsDepartment of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
Zhenyu ZhangDepartment of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
Werner BudtsDivision of Structural and Congenital Cardiology, University Hospitals Leuven, Leuven, Belgium.
Alexander Van De BruaeneDivision of Structural and Congenital Cardiology, University Hospitals Leuven, Leuven, Belgium.
KU Leuven · BEUniversity of Gothenburg · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsInformation on the prevalence, outcome and factors associated with heart failure in patients with adult congenital heart disease (CHD) (ACHD-HF) is lacking. We aimed at assessing the prevalence and outcome of ACHD-HF, the variables associated with ACHD-HF, and the differences between major anatomical/pathophysiological ACHD subgroups. METHODS AND

resultsWe included 3905 patients (age 35.4 ± 13.2 years) under active follow-up in our institution (last visit >2010). Outcome of ACHD-HF cases was compared with sex- and age-matched cases. Univariable and multivariable binary logistic regression with ACHD-HF diagnosis as a dependent variable was performed. Overall prevalence of ACHD-HF was 6.4% (mean age 49.5 ± 16.7 years), but was higher in patients with cyanotic CHD (41%), Fontan circulation (30%), and a systemic right ventricle (25%). All-cause mortality was higher in ACHD-HF cases when compared with controls (mortality rate ratio 4.67 (2.36-9.27); P = 0.0001). In multivariable logistic regression analysis, age at latest follow-up [per 10 years; odds ratio (OR) 1.52; 95% confidence interval (CI) 1.31-1.77], infective endocarditis (OR 4.11; 95%CI 1.80-9.38), history of atrial arrhythmia (OR 3.52; 95%CI 2.17-5.74), pacemaker implantation (OR 2.66; 95% CI 1.50-4.72), end-organ dysfunction (OR 2.41; 95% CI 1.03-5.63), New York Heart Association class (OR 9.28; 95% CI 6.04-14.25), heart rate (per 10 bpm; OR 1.27; 95% CI 1.08-1.50), ventricular dysfunction (OR 3.62; 95% CI 2.54-5.17), and pulmonary hypertension severity (OR 1.66; 95% CI 1.21-2.30) were independently related to the presence of ACHD-HF. Some variables (age, atrial arrhythmia, pacemaker, New York Heart Association, and ventricular dysfunction) were related to ACHD-HF in all anatomical/physiological subgroups, whereas others were not.

conclusionsACHD-HF is prevalent especially in complex CHD and is associated with poor prognosis. Our data provide insight in the factors related to ACHD-HF including differences between specific anatomical and physiological subgroups.

Indexed as

Heart Defects, CongenitalHeart FailureHypertension, PulmonaryAdultAgedHumansMiddle AgedPrevalenceRisk FactorsYoung AdultACHDAll-cause mortalityCongenitalHeart failure

Identifiers

PMID33960724
PMCPMC8318399
OpenAlexW3157595545

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.